Member Info for SocialistB

@Saint68

I do not disagree that a lower percentage would mean more money to you and me and every other investor.

10 percent, more money to us.

5 percent, even more money to us, but at risk of being seen as to little engagement from the BOD.

1 Percent, even more money to all of us, but most definitely it would be perceived as a negative.

Question is, if we think management getting a 20 percent share is to high a cut.

In HEMOGENYX instance I do not think it is.

In a different company I might see it it differently, years down the line from now, depending how this unfolds I might not be happy with this either.

But right here, right now, management have contracted themselves to buy at a premium to current share price, it is not just given to them for free.

I like that, and if we get billions, or enough money to a special dividend and progressing CBR or my absolute dream scenario, enough cash flow from Estonia to go all the way ourselves and start the journey to become a major ourselves, then I sm absolutely fine with the RNS' last Friday.

Good morning Saint68

Could my post have been worded differently, YES

Should my post have been worded differently, MAYBE

My initial reaction Friday, was not jumping in the air, throwing pump fists, being jubilant.

What they did was allowing themselves to add up to some 11 million pounds to the coffer at some point in the future at a premium to today's share price.

They might do it, they might not.

I suspect they will first do so, when some kind of deal is on the table, meaning HEMOGENYX does not need to raise further capital at that point.

We can always walk around being angry they were not down in the mud with us a year ago.

Back then I bought some shares at less then 2 pounds.

They are now committed to by at a premium to today's price and more then 4 times higher then what I paid for some of my shares.

Personally, I do not find 20 percent excessive.

Is it common or not, I don't know, I don't care

Does it feel like an excessive stake, not to me.

Could they have bought over the years, sure, but exactly where would they get the money to do so, I assume from salary paid by investors.

And yes, I do feel the company is de-risked at this stage.

Why the Management Buy-In Price Doesn't Matter (And Why I’m All In)

I’ve been doing some deeper thinking about management bringing their total options pool up to 20.7%. On Friday, the timing felt a bit frustrating because the company is finally de-risked. But after looking closely at the details of the RNS announcement, my perspective has completely shifted.

Here is why this is actually a massive win for all of us:

They are locking in a high target price: Look at the strike price—it is set at £8.00 per share. This isn’t a cheap giveaway or a low-ball entry; management is legally binding their personal financial upside to a massive future milestone. They only win if the company scales massively from here.

The price doesn't matter because we don't need the cash: Some might wonder why we are issuing options if the company doesn't desperately need the money right now. But that's exactly the point. Because we don't need immediate cash, this transaction isn't about survival—it's about alignment and incentivization.

I want them to make billions: If management exercises these options at £8.00 and multiplies their investment many times over, it means the share price has absolutely skyrocketed. I have zero issues with management getting incredibly wealthy from this, because for them to win that big, the rest of us have to win even bigger.

Whether we sell the entire company for multiple billions or secure a massive deal for HGCT1, we want a management team that is aggressively incentivized to hold out for the highest possible bidder. This 20.7% total pool ensures they are locked in and driving hard toward the finish line.

@TimberTrader,

Thanks for sharing.

I love that we are giving back to the community.

And it gets even better when we could potentially benefit from it ourselves.

And a nice little self advertisement "One of Australia's biggest gold producers"

Good call supporting an essential infrastructure requirement in Western Australia.

@JustHereForHemo and jezza1977

Thank you for your input.

Glad to hear there have been a lot of buying going on in the background.

I have done my bid as well in that regard.

(Not that it count for much:-(

And without that buying, the share price could potentially have driftet lower.

I do however think jezza1977, might be onto something when he says, on hold for 6 months and people have forgotten about this share, because otherwise why aren't there 10 buyers for each share offered for sale?

The theory of supply and demand, craves that the share price should have gone up if the demand is high enough.

So, I have to conclude, that even though the demand has been high enough to absorb what has been offloaded, it has not been high enough to raise the share price.

In my view it should have gone up with all the positive news, I mentioned earlier.

So the question remains what will the inflection point be?

Injection or 14 day post injection, with a clean slate, nothing to worry about from a safety point of view.

Or something completely different?

I understand that someone might wish to sell.

They might need the money now, can't wait another second, because......?

They might wish to suppress the share price, they might have ulterior motives (but this is conspiracy theory)

What I do not understand is the lack of frantic buying, based on all the good news of enough money in the coffee, progress on every single front, Estonia, Patient 4, CBR, the companys stated willingness to sell or licence a product.

The market should be going crazy, but isn't.

Being paranoid about the doze escalation, that theory, does help explain why there is not a que of 10 buyers to every share offered to the market these days.

We have recently had what I consider to be great news, so I cannot help but wonder why we have a stagnant share price.

And what the next inflection point will be.

​We have the cash for the year.

We know the first pediatric patient and the adult Patient 4 are hitting the clinic.

On paper, these are massive milestones—so why is the share price still treading water?

​Here’s my take on why the market is holding back, and why "Injection Day" might be a double-edged sword.

​I suspect the market is pricing in the dose escalation risk.

We’re moving to a higher dose for the next adult patient.

While we’ve already seen the half-dose works, the market is paranoid about the unknown.

​In CAR-T trials like HG-CT-1, the first 7 to 14 days are the "danger zone" for side effects like CRS (Cytokine Release Syndrome) or ICANS.

I believe big money is sitting on the sidelines until they know those first 14 days pass without a hitch.

​Personally, I see a risk if the company announces an injection the second it happens.

In my view, that could actually drive the price lower in the short term because it starts the clock on that 14-day risk window.

​My Ideal Scenario

​The timing of these updates is largely in the hands of the hospital running the trial, not just the company.

However, my hope is that when we finally get the RNS, it says:

​"The patient was injected 48 hours ago (or even a week ago) and is doing well."

​If the news arrives with a "so far, so good" safety buffer already built-in, that’s when we finally break the stagnation.

Until then, the market seems content to wait for the data to prove the safety of the higher dose.

This is what makes most sense to me, when I wonder about the current share price stagnation, because with money in the coffer for the rest of the year, being ready to inject the next set of patients, and confirmation Estonia route is still being persued, we ought to be way north of where we are.

​Bottom line is, it’s a risky period, but once we clear that 14-day hurdle, the path to a real inflection point—and a potential buyout or partnership—becomes much clearer.

Yesterday's RNS confirmed the Estonia Strategy.

We now have 3 million extra in the coffer, some will be used to activate the hospital exemption pathway in Estonia.

Manufacturing hardware is already in place, and tech transfer with Cellin is starting immediately.

But unlike the injections given in the U.S. this isn't just a trial; it’s a revenue-generating engine that validates the asset in a real-world setting with datavaluations.

We’ve seen other biotech assets sell for billions once big pharmaceutical companies believe they are onto something valuable.

I claim that if HG-CT-1 shows a clean dose escalation in the U.S. and additional robust real-world data from Estonia, the asset becomes a prime acquisition target worth many more BILLIONS then the current going rate, simply because we have extra data.

And this is the beautiful part, we are being paid to gather that extra data, and this is about as atypical as can be, because most pharmaceutical companies pay to gather data.

They do not get paid while gathering data.

With that in mind, raising £3M to not just de-risk a therapy with billion-dollar potential but also to speed up the data creation and produce early income is efficient capital allocation and share dilution.

What do you think? Is the roughly 5% dilution worth the accelerated path to a potential higher buyout and early income.

Sorry autocorrect took over.

Was meant to say:

"and then again help FUNDING the company I believe so strongly in."

@pumpky

You said:

"I/we await confirmation that NONE of the Uber positives have Sold a single share to purchase their cheap warrants"

You make it sound like that would be a bad thing.

Is that what you mean or do I misunderstand you?

If I have not misunderstood you, please explain why it would be a bad thing.

The way I see it, the more money to the company the better.

And people who have supported HEMOGENYX directly in the past and been allocated warrants as a result, have every right to redeem them.

And if they are on low income as you alluded earlier today, then there are maybe not any other options then to sell some shares in an investment to buy the warrants that would otherwise expire.

HEMOGENYX win as they get more money in the coffer.

As an investor in HEMOGENYX, I win because the company gets more money in the coffer.

The only one loosing out is the investors who have to sell out of an investment to buy the warrants they are entitled to before they expire.

Especially if they have to sell some HEMOGENYX shares to buy the warrants.

In the end they end up with less shares in HEMOGENYX, then if they had a big income from which they could simply buy the warrants.

One thing is for sure, I'd wish I had been smart enough to sign up back in the day to help fund the company directly and receive warrants as a thank you and been able to sell some shares today at a higher price and then again help finding the company I believe so strongly in.

Alas, I was not that smart or brave, so I just have to sit on the sideline and be thankful and grateful to those people who have the ability to keep funding HEMOGENYX.

A heartfelt thank you guys.

@Saint68

Hear Hear

@Saint68

I chose to see the radio silence regarding CBR in the exact same light as I see the current situation regarding HG-CT-1.

No news, is good news.

The absence of bad news speaks volumes to me, as I am of the opinion they would have to tell us if things went wrong with CBR.

I have heard so many good news regarding CBR, effective against some cancers, possible effective against all known viruses to man.

And definitely effective against some of the worst ones we are dealing with in this day of age.

And effective delivery methods.

Plenty of positive news and confirmed RNS' out there.

Just radio silence.

And it means the market does not know.

That will hopefully be our gain one day.

Good morning HereforHemo.

Thanks for your reply.

If I have not misunderstood you, then in your scenario we will have invested in one company, but become shareholders in 2.

Presumably with the same amount of shares in each.

I do not believe the market has woken to the potential of CBR.

When they do, we're of to the races.

Imagine being an investor in 2 highly successful pharma companies:-)

And it all started with just one investment.

@HereforHemo

Logically I can follow your thoughts in comparison to Spero.

As the same could potentially happen here on news of a similar deal regarding CDX.

But, now my logic starts to look at things differently, HG-CT-1 and HEMOGENYX regarding these 2 products does not any longer become a must have for big pharma.

We will not experience a bidding war.

Who would want to offer billions for HG-CT-1 when CDX has been snapped up by a competitor?

The consensus on this board have for a long time been that anyone who buys HG-CT-1 would also want CDX.

But that does not automatically work in reverse, that anyone buying into CDX, would also want HG-CT-1.

And if nobody wants to pay good money for it, then why sell?

If that was to be the case we would be better if keeping HG-CT-1 as a cash generator, so we can progress with CBR.

After Estonia, could it be – Japan, here we come.

Japans Pharmaceuticals and Medical Devices Act (PMD Act) contains the Conditional and Time-Limited Approval pathway.

Unlike traditional drugs that require massive Phase III trials to prove efficacy before sale, this act allows approval based on preliminary clinical data that "predicts" efficacy, provided safety is confirmed.

In March 2026, Japan officially approved the world's first commercial stem-cell treatments derived from induced pluripotent stem (iPS) cells.

ReHeart (Cuorips Inc.): A treatment for severe heart failure caused by ischemic cardiomyopathy.

It involves placing coin-shaped "sheets" of heart muscle cells (grown from donor iPS cells) onto the patient's heart to stimulate new blood vessel growth and improve cardiac function.

Back to the Conditional and Time-Limited Approval pathway.

Could this be a way forward for HEMOGENYX and HG-CT-1in Japan?

For me, it looks like we should be able to qualify, based on what HG-CT-1 has proven so far in regard to safety and efficacy.

I think it is great that there are either more or alternate options out there.

The future is bright, at least that is how I see it.

@HereforHemo

Thank you for another great post of yours.

I hope you're being a bit conservative with the numbers, but then again the share price should not be this low, taking into consideration what we got and were we are with regard to HG-CT-1.

But since you mentioned CDX and CBR in the same breath as with HG-CT-1.

An offer from a big pharma for 100 quid a share would be a downright offense.

If we are to get into the plural BILLIONS territory, we need around 300 a share.

But frankly that is way to cheap.

@Matt5

I personally hope your right that there is no buyout deal in the wings at the moment.

We simply would not get full value at this stage.

HG-CT-1 will increase in value as more Patients are treated successfully.

And thanks to some generous investors we now have the money needed to progress to patients 4 and 5.

We have been told that the completion of the transfer to MADE SCIENTIFIC will be concluded soon -ish.

I hope and believe that it will be possible to produce the HG-CT-1 in the USA and administer it in Estonia in the near future.

It would be a great start, then production can always be set up there.

If I am right in my assumptions, then HEMOGENYX will soon be cash generative.

If the profit is significant, then Mr Sandler won't have a problem advancing CDX and CBR further.

That would be a fantastic position to be in.

If the plan is to sell HG-CT-1, the value has increased.

If the plan is to sell CDX, it's value will have increased as well, if further research has validated it (and of course it has:-)

If the plan is to sell CBR.....

I'll scream NO at the top of my lungs.

Either way, money generated in Estonia can be used on further research with our other candidates and if promising results show, it will increase the value of the candidates.

Further research is though also where the risk lies at the moment.

There is no guarantee that when the dose increases it won't have a negative effect of some kind.

But hopefully that can be mitigated at the hospital if that should happen.

And maybe it will tell us that we already have an optimal dose.

The one already given, which was a half dose, for security reasons.

If that is the case, it's rather potent.

Again, value creation.

But frankly, I personally hope to build a company on three great products instead of just 1.

Dead or alive – Does it really matter?

To the Patient and their nearest and dearest – of course it does.

But perhaps not necessarily from a progressive perspective for Hemogenyx.

The science is still good (and I will claim way better than good as I believe Patient 1 to be alive)

In an RNS from 29 Oct 2025, Hemogenyx reported DSMB clearance, cohort completion and no safety hold.

That timeline makes an infusion proximate fatal toxicity (days–weeks after infusion) unlikely to have occurred without being flagged publicly.

Therefore, if Patient 1 died before their 12-month anniversary, the most plausible explanations—given available RNSs—are disease progression or unrelated causes, not an acute infusion-related toxicity.

The company’s continued dosing, DSMB clearance and pediatric expansion are concrete signals that no early treatment-related fatal event was judged by investigators/regulators to require trial suspension.

We recently surpassed the 1-year mark since Patient 1 received their injection, and we can expect an update soon on their progress.

Great for them and could potentially be great for the share price as well.

Other news that could affect the share price has been discussed in great detail by others – I am particularly a fan of the Estonia Avenue.

It would be a dream come true for me if Hemogenyx can keep HG-CT-1 and earn a good penny on treating patients in their own name and right.

The more Data and money we gain from Estonia, the more likely we are to be able to fund CDX ourselves, especially if MD Anderson is keen to look into it after seeing HG-CT-1 in action first hand.

My understanding of CDX was that nobody dared to touch it years ago; it was too innovative an approach.

If there is interest from MD Anderson and Mr Sandler has a plan and a possible funding route, that could help explain why there has been no talk yet of a deal with a big pharma company.

I would love to go all alone and have the two products as a company builder.

In a scenario where there is a good income stream from Estonia for years to come, it should be possible to loan a few million and crack on with both CDX and CBR.

And it would not cause any further dilution.

Fantastic

Should Mr Sandler be in serious talks with a big pharma company, then it is still most definitely worth pursuing further proof of the CDX, before signing on the dotted line – it is all value-creating.

But yeah, why only count on CBR as the company builder?

Why not have 3 fantastic candidates and, hopefully, 3 income streams later on?

@checkricky

Thanks for the link.

Sounds interesting as a starting point.

For a second , I even wondered if I could go there, just to educate myself on what's going on in this area of medicine.

That is until I saw the price for participation.

1799 to 4997 for a ticket.

No thank you.

Not for me.

And I am glad Mr Sandler is not there either paying that price to participate.

I stopped looking into what it was about in more depth after seeing the price.

What I saw beforehand regarding being able to scale up and so forth.

To me it seems HEMOGENYX are already on the right track.

So, in my view nothing lost by Mr Sandler not being there.

But thank you for the link

I'm just playing along here, following the line of thought.

If there truly were no news until, let's say the second week of April 2026, just to be on the safe side.

I agree that there is a huge risk that the share price will decline.

I say that because, I would be hugely surprised if some of the shares are not in inpatient hands.

New tax year, will mean that those Lth's who already have filled their ISA this year, will get a shot at doing so again.

Good for them

When I said no news, I meant no news.

No news are good news.

It means there is nothing bad to report regarding the treatment and the patients.

That in itself is very valuable.

It takes both Patient 1&2 comfortably beyond their first and their half year anniversaries.

Remember Patient 3, 28 days after injection?

(Otherwise look it up, September RNS' 2025)

But in all likelihood, there will be plenty of news before April 2026.

We have been told the transfer to MADE SCIENTIFIC, is almost done.

In my view that opens up the door to continue the trials in the US, but also the Estonia avenue.

Either way, there is no guarantee that the share price will go up. (Even though, I think from a logical point it should)

But one thing is guaranteed, the cheaper the share price, the more I get for my money.

I quite like that:-)